Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Research Article

. 2021; 12(4): 702-704


Usefulness of serum Cystatin C in comparison to serum creatinine as an early marker of acute renal disease- An Original Research

Dr. Vishal Bhargava,Dr.Krishana Gopal, Dr. Ram A Rawat, Dr.Richa Sijoria.

Abstract
Background: Acute kidney injury (AKI) is characterized by rapid decline in glomerular filtration rate (GFR).
Cystatin C is 13-kDa cysteine protease inhibitor that is produced by all nucleated cells at a constant rate. Hence;
the present study was conducted with the aim of assessing the usefulness of serum Cystatin C in comparison to
serum creatinine as an early marker of acute renal disease.
Materials & methods:100 healthy subjects and 100 AKI patients were enrolled. Information such as age,
gender, height, weight, comorbidities, personal history, drug history, presenting complaints and laboratory
investigationswas obtained. The serum cystatin C and serum creatinine values were measured simultaneously
and analysed. In the AKI study group, they were taken within 24 hours of onset of injury. All the results were
recorded and analysed by SPSS software.
Results:Mean Serum Cystatin C levels among the patients of the AKI group and the control group was 2.35
mg/dL and 0.91 mg/dL respectively.Mean Serum creatinine levels among the patients of the AKI group and the
control group was 1.97 mg/dL and 0.68 mg/dL respectively. Significant results were obtained while comparing
the mean serum Cystatin C levels and Serum creatinine levels among the patients of the study group and the
control group. Significant correlation of serum Cystatin C levels with AKI in comparison to serum creatinine
levels.
Conclusion: In comparison to serum creatinine, Serum cystatin C is a better marker of renal function in AKI
patients.

Key words: Cystatin C, Acute renal disease



Similar Articles

Exploring the Alzheimer's disease neuroepigenome: recent advances and future trends.
Zhang H, Elefant F
Neural regeneration research. 2022; 17(2): 325-327

Editorial: Novel therapeutic approaches in chronic kidney disease and kidney transplantation: the draw of evolving integrated multimodal approaches in the targeted therapy era.
Tantisattamo E, Hanna RM, Kalantar-Zadeh K
Current opinion in nephrology and hypertension. 2022; 31(1): 1-5

Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
Goulding SR, Anantha J, Collins LM, Sullivan AM, O'Keeffe GW
Neural regeneration research. 2022; 17(1): 38-44

Differentiating Human Pluripotent Stem Cells to Vascular Endothelial Cells for Regenerative Medicine, Tissue Engineering, and Disease Modeling.
Bertucci T, Kakarla S, Kim D, Dai G
Methods in molecular biology (Clifton, N.J.). 2022; 2375(): 1-12

Presenilin mutations and their impact on neuronal differentiation in Alzheimer's disease.
Hernandez-Sapiens MA, Reza-Zaldívar EE, Márquez-Aguirre AL, Gómez-Pinedo U, Matias-Guiu J, Cevallos RR, Mateos-Díaz JC, Sánchez-González VJ, Canales-Aguirre AA
Neural regeneration research. 2022; 17(1): 31-37


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.



ScopeMed Web Sites